| Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition WHD Hallett, E Ames, M Motarjemi, I Barao, A Shanker, DL Tamang, ... The Journal of Immunology 180 (1), 163-170, 2008 | 166 | 2008 |
| TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer E Cretney, A Shanker, H Yagita, MJ Smyth, TJ Sayers Immunology and cell biology 84 (1), 87-98, 2006 | 128 | 2006 |
| Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients ML Ascierto, MO Idowu, Y Zhao, H Khalak, KK Payne, XY Wang, ... Journal of translational medicine 11, 1-11, 2013 | 115 | 2013 |
| NK cells: immune cross-talk and therapeutic implications A Malhotra, A Shanker Immunotherapy 3 (10), 1143-1166, 2011 | 115 | 2011 |
| CD8 T cell help for innate antitumor immunity A Shanker, G Verdeil, M Buferne, EM Inderberg-Suso, D Puthier, F Joly, ... The Journal of Immunology 179 (10), 6651-6662, 2007 | 112 | 2007 |
| Critical neurotransmitters in the neuroimmune network TW Hodo, MTP De Aquino, A Shimamoto, A Shanker Frontiers in Immunology 11, 523925, 2020 | 111 | 2020 |
| CD8+ T lymphocyte and NK cell network: circuitry in the cytotoxic domain of immunity RV Uzhachenko, A Shanker Frontiers in immunology 10, 461621, 2019 | 106 | 2019 |
| Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Agonist Antibody A Shanker, AD Brooks, CA Tristan, JW Wine, PJ Elliott, H Yagita, ... Journal of the National Cancer Institute 100 (9), 649-662, 2008 | 100 | 2008 |
| Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth Y Huang, L Lin, A Shanker, A Malhotra, L Yang, MM Dikov, DP Carbone Cancer research 71 (19), 6122-6131, 2011 | 84 | 2011 |
| Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex AD Brooks, KM Jacobsen, W Li, A Shanker, TJ Sayers Molecular Cancer Research 8 (5), 729-738, 2010 | 71 | 2010 |
| Modulatory effects of bortezomib on host immune cell functions ST Pellom Jr, DF Dudimah, MC Thounaojam, TJ Sayers, A Shanker Immunotherapy 7 (9), 1011-1022, 2015 | 69 | 2015 |
| Cooperativity of adaptive and innate immunity: implications for cancer therapy A Shanker, FM Marincola Cancer Immunology, Immunotherapy 60, 1061-1074, 2011 | 63 | 2011 |
| Multivalent forms of the Notch ligand DLL-1 enhance antitumor T-cell immunity in lung cancer and improve efficacy of EGFR-targeted therapy AK Biktasova, DF Dudimah, RV Uzhachenko, K Park, A Akhter, ... Cancer research 75 (22), 4728-4741, 2015 | 57 | 2015 |
| Common gamma chain cytokines in combinatorial immune strategies against cancer SR Pulliam, RV Uzhachenko, SE Adunyah, A Shanker Immunology letters 169, 61-72, 2016 | 56 | 2016 |
| Is thymus redundant after adulthood? A Shanker Immunology letters 91 (2-3), 79-86, 2004 | 56 | 2004 |
| Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity A Shanker, AD Brooks, KM Jacobsen, JW Wine, RH Wiltrout, H Yagita, ... Cancer research 69 (16), 6615-6623, 2009 | 53 | 2009 |
| Challenges and future perspectives of T cell immunotherapy in cancer MTP de Aquino, A Malhotra, MK Mishra, A Shanker Immunology letters 166 (2), 117-133, 2015 | 50 | 2015 |
| Development of proteasome inhibitors as therapeutic drugs ST Pellom Jr, A Shanker Journal of clinical & cellular immunology, 5, 2012 | 50 | 2012 |
| Adaptive control of innate immunity A Shanker Immunology letters 131 (2), 107-112, 2010 | 49 | 2010 |
| Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity EE Tchekneva, MUL Goruganthu, RV Uzhachenko, PL Thomas, ... Journal for immunotherapy of cancer 7, 1-17, 2019 | 45 | 2019 |
